Paradigm Health has successfully raised an additional $77 million in funding, bringing its total capital to $253 million, as it seeks to revolutionize the clinical trial landscape through artificial intelligence. The startup’s recent acquisition of a unit from Flatiron Health, a subsidiary of Roche, underscores its commitment to making clinical trials more efficient and equitable.
This strategic move comes at a time when the pharmaceutical industry is increasingly looking to AI to streamline processes, reduce costs, and improve patient recruitment for clinical trials. By leveraging AI technology, Paradigm aims to address longstanding challenges in trial enrollment, which often suffer from inefficiencies and biases.
The implications of this partnership are significant for the B2B pharma sector, particularly for professionals in regulatory, QA/QC, and CMC roles. As AI continues to gain traction, companies may need to adapt their strategies and operations to remain competitive in a rapidly evolving market.
Start your 7-day trial and see what the database can do →
